KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.70

-0.42%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

At a Glance

Live Snapshot
Market Cap$87.90M
EPS-2.8500
P/E Ratio-1.65
Earnings Date08/12/2026

klrs

Interest Expense

Last Annual Value

1.44M

3-Year CAGR

83%

5-Year CAGR

%

10-Year CAGR

%

KT

Kalaris Therapeutics Inc Competitors Analysis of Interest Expense

KLRS · NASDAQ
CompanyInterest Expense
CAGR 3Y
CAGR 5Y
CAGR 10Y
1.44M
28.1%N/AN/A 
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
1.60M
0.8%161.9%N/A
0.00
N/AN/AN/A
90.00K
-42.9%-23.6%N/A
0.00
N/AN/AN/A
KT

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.7, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

Intrinsic Value
Current Price: $4.7